BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 20883737)

  • 1. Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model.
    Kim HS; Park HM; Park JS; Sohn HJ; Kim SG; Kim HJ; Oh ST; Kim TG
    Vaccine; 2010 Nov; 28(49):7787-96. PubMed ID: 20883737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient antitumor immunity in a murine colorectal cancer model induced by CEA RNA-electroporated B cells.
    Park MY; Kim HS; Woo SJ; Kim CH; Park JS; Sohn HJ; Kim HJ; Oh ST; Kim TG
    Eur J Immunol; 2008 Aug; 38(8):2106-17. PubMed ID: 18624349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide.
    Oh ST; Kim CH; Park MY; Won EH; Sohn HJ; Cho HI; Kang WK; Hong YK; Kim TG
    Vaccine; 2006 Apr; 24(15):2860-8. PubMed ID: 16443309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient co-transduction of adenoviral vectors encoding carcinoembryonic antigen and survivin into dendritic cells by the CAR-TAT adaptor molecule enhance anti-tumor immunity in a murine colorectal cancer model.
    Kim HS; Kim CH; Park MY; Park JS; Park HM; Sohn HJ; Kim HJ; Kim SG; Oh ST; Kim TG
    Immunol Lett; 2010 Jun; 131(1):73-80. PubMed ID: 20211203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity.
    Saha A; Chatterjee SK; Foon KA; Primus FJ; Bhattacharya-Chatterjee M
    Cancer Res; 2003 Jun; 63(11):2844-54. PubMed ID: 12782590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The optimal interval for dendritic cell vaccination following adoptive T cell transfer is important for boosting potent anti-tumor immunity.
    Park MY; Kim CH; Sohn HJ; Oh ST; Kim SG; Kim TG
    Vaccine; 2007 Oct; 25(42):7322-30. PubMed ID: 17889413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer.
    Saha A; Chatterjee SK
    Scand J Immunol; 2010 Feb; 71(2):70-82. PubMed ID: 20384858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
    Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
    Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cell therapy with interferon-alpha synergistically suppresses outgrowth of established tumors in a murine colorectal cancer model.
    Ishii S; Hiroishi K; Eguchi J; Hiraide A; Imawari M
    Gene Ther; 2006 Jan; 13(1):78-87. PubMed ID: 16107857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
    Kudo-Saito C; Schlom J; Camphausen K; Coleman CN; Hodge JW
    Clin Cancer Res; 2005 Jun; 11(12):4533-44. PubMed ID: 15958639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs.
    Correale P; Del Vecchio MT; La Placa M; Montagnani F; Di Genova G; Savellini GG; Terrosi C; Mannucci S; Giorgi G; Francini G; Cusi MG
    J Immunother; 2008; 31(2):132-47. PubMed ID: 18481383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
    Fuchs CS; Marshall J; Mitchell E; Wierzbicki R; Ganju V; Jeffery M; Schulz J; Richards D; Soufi-Mahjoubi R; Wang B; Barrueco J
    J Clin Oncol; 2007 Oct; 25(30):4779-86. PubMed ID: 17947725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
    Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
    J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice.
    Zeytin HE; Patel AC; Rogers CJ; Canter D; Hursting SD; Schlom J; Greiner JW
    Cancer Res; 2004 May; 64(10):3668-78. PubMed ID: 15150127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J; Saffold S; Cao X; Krauss J; Chen W
    J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing.
    Chakraborty M; Abrams SI; Coleman CN; Camphausen K; Schlom J; Hodge JW
    Cancer Res; 2004 Jun; 64(12):4328-37. PubMed ID: 15205348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.